Chemokine

Olatec Therapeutics Enrolls its First Patients in a Phase 2 Clinical Trial in COVID-19 with its Selective NLRP3 Inhibitor, Oral Dapansutrile

Tuesday, October 27, 2020 - 1:34pm

In a previous clinical trial, dapansutrile was observed to suppress IL-1 and downstream cytokines and chemokines of the inflammatory cascade in patients with the acute gout flares.

Key Points: 
  • In a previous clinical trial, dapansutrile was observed to suppress IL-1 and downstream cytokines and chemokines of the inflammatory cascade in patients with the acute gout flares.
  • In a second clinical trial in patients with persistent heart failure, the dapansutrile treatment group showed improvement in heart function compared to the placebo group.
  • Activation of NLRP3 initiates Cytokine Release Syndrome (CRS), an intense inflammatory response, that is frequently documented in COVID-19 patients.
  • By downregulating NLRP3 activation, dapansutrile could mitigate against the serious inflammatory effects from the SARS-CoV-2 infection, particularly in high-risk COVID-19 patients.

ONCURIOUS I-O Portfolio Directed at Boosting T Cell Influx and Activity in Solid Tumors Announcing First Preclinical Proof of Concept in Proprietary CCR8 Treg Program

Thursday, October 22, 2020 - 5:47pm

Preclinical Proof of Concept for Companys priority I-O program, aiming at depleting regulatory T cells (Tregs) by targeting C-C motif chemokine receptor 8 (CCR8)

Key Points: 
  • Preclinical Proof of Concept for Companys priority I-O program, aiming at depleting regulatory T cells (Tregs) by targeting C-C motif chemokine receptor 8 (CCR8)
    Initiating lead optimization phase in proprietary CCR8 Treg Program.
  • This important milestone follows Oncurious decision to focus its development activities on a pipeline of promising novel immune-oncology targets and drug discovery projects.
  • Oncurious is now accelerating its efforts towards initiation of preclinical development of the therapeutic antibody program in early 2021.
  • Next to the anti-CCR8 program, Oncurious is focusing on 2 other programs aimed at boosting anti-tumor T cell influx and activity in immune excluded tumors.

Viral 'molecular scissor' is next COVID-19 drug target: Coronavirus uses enzymatic cutter for virus production and to disable essential immune proteins

Sunday, October 18, 2020 - 12:10pm

The researchers are from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) and the Wroclaw University of Science and Technology.

Key Points: 
  • The researchers are from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) and the Wroclaw University of Science and Technology.
  • Information gleaned by the American team helped Polish chemists to develop two molecules that inhibit the cutter, an enzyme called SARS-CoV-2-PLpro.
  • "It stimulates the release of proteins that are essential for the virus to replicate, and it also inhibits molecules called cytokines and chemokines that signal the immune system to attack the infection," Dr. Olsen said.
  • Visit our online Newsroom , and to see how we are battling COVID-19, read inspiring stories on Impact .

RAPT Therapeutics to Present at Upcoming Virtual Investor Conferences

Thursday, September 3, 2020 - 1:00pm

Please connect to the website 10 minutes prior to the presentations to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

Key Points: 
  • Please connect to the website 10 minutes prior to the presentations to ensure adequate time for any software downloads that may be necessary to listen to the webcast.
  • RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases.
  • Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases.
  • RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively.

X4 Pharmaceuticals to Present and Participate in the Canaccord Genuity’s 40th Annual Growth Conference

Monday, August 10, 2020 - 10:07pm

A live webcast of the presentation will be available on the investor section of the X4 Pharmaceuticals website at www.x4pharma.com .

Key Points: 
  • A live webcast of the presentation will be available on the investor section of the X4 Pharmaceuticals website at www.x4pharma.com .
  • After the live webcasts, the events will remain archived on the X4 Pharmaceuticals website for approximately 90 days.
  • The Companys lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy.
  • X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters inCambridge, Massachusettsand at its research facility inVienna,Austria, and is discovering and developing additional product candidates.

Orion Biotechnology Receives Funding to Test OB-002 for Treatment of COVID-19

Thursday, July 30, 2020 - 3:51pm

OB-002 is the first of a new class of drugs, called Chemokine Analogs, being developed by Orion Biotechnology leveraging its proprietary Drug Discovery Platform.

Key Points: 
  • OB-002 is the first of a new class of drugs, called Chemokine Analogs, being developed by Orion Biotechnology leveraging its proprietary Drug Discovery Platform.
  • CCL5 (RANTES) is an inflammatory chemokine which has been shown to play an important role in the development of ARDS.
  • We are delighted to receive advisory services and funding from NRC IRAP, which will contribute to further innovative research towards ending the COVID-19 global pandemic, stated Mark Groper, President and CEO of Orion Biotechnology.
  • Ross MacLeod Orion Biotechnology Canada Ltd. +1 343.291.1032 ross@orionbiotechnology.com

RAPT Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference

Wednesday, June 17, 2020 - 1:00pm

A live webcast and audio archive of the presentation may be accessed on the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations .

Key Points: 
  • A live webcast and audio archive of the presentation may be accessed on the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations .
  • Please connect to the website 10 minutes prior to the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.
  • RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases.
  • RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively.

RAPT Therapeutics to Present at the Jefferies Virtual Global Healthcare Conference

Tuesday, May 26, 2020 - 1:00pm

A live webcast and audio archive of the presentation may be accessed on the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations .

Key Points: 
  • A live webcast and audio archive of the presentation may be accessed on the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations .
  • Please connect to the website 10 minutes prior to the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.
  • RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases.
  • RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively.

RAPT Therapeutics to Present at the UBS Virtual Global Healthcare Conference

Tuesday, May 12, 2020 - 1:00pm

A live webcast and audio archive of the presentation may be accessed on the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations .

Key Points: 
  • A live webcast and audio archive of the presentation may be accessed on the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations .
  • Please connect to the website 10 minutes prior to the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.
  • RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases.
  • RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively.

Sengenics Launches the ImmuKyne Protein Array to Identify Autoantibodies Implicated in Development of ARDS in COVID-19

Thursday, April 23, 2020 - 2:00pm

A cytokine is a signalling molecule that the body releases to trigger inflammation in an attempt to fight against the infection.

Key Points: 
  • A cytokine is a signalling molecule that the body releases to trigger inflammation in an attempt to fight against the infection.
  • The ImmuKyne protein array is the latest addition to the Sengenics virology product line and demonstrates the companys commitment to contribute to the global effort to fight the COVID-19 pandemic.
  • ImmuKyne is the first KREX-based protein array that enables simultaneous screening of over 300 immunomodulatory autoantigens comprising clinically significant protein classes that may be implicated in ARDS, such as cytokines, chemokines and interleukins.
  • For further information about the ImmuKyne protein array, please contact us at covid@sengenics.com .